K. E. Price

1.5k total citations
54 papers, 1.1k citations indexed

About

K. E. Price is a scholar working on Pharmacology, Molecular Medicine and Molecular Biology. According to data from OpenAlex, K. E. Price has authored 54 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Pharmacology, 23 papers in Molecular Medicine and 13 papers in Molecular Biology. Recurrent topics in K. E. Price's work include Antibiotic Resistance in Bacteria (23 papers), Antibiotics Pharmacokinetics and Efficacy (23 papers) and Antimicrobial Resistance in Staphylococcus (10 papers). K. E. Price is often cited by papers focused on Antibiotic Resistance in Bacteria (23 papers), Antibiotics Pharmacokinetics and Efficacy (23 papers) and Antimicrobial Resistance in Staphylococcus (10 papers). K. E. Price collaborates with scholars based in United States, United Kingdom and Germany. K. E. Price's co-authors include R. E. Buck, T. A. Pursiano, F. Leitner, M Misiek, M. D. DeFuria, John C. Godfrey, Hiroshi Kawaguchi, R E Kessler, J. Lein and Paul Siminoff and has published in prestigious journals such as Journal of Bacteriology, The American Journal of Medicine and Journal of Medicinal Chemistry.

In The Last Decade

K. E. Price

53 papers receiving 893 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
K. E. Price United States 17 652 490 279 200 164 54 1.1k
J. Allan Waitz United States 21 632 1.0× 428 0.9× 449 1.6× 194 1.0× 209 1.3× 56 1.4k
H. Wallick United States 11 553 0.8× 315 0.6× 611 2.2× 239 1.2× 172 1.0× 16 1.6k
R. T. TESTA United States 20 663 1.0× 502 1.0× 544 1.9× 166 0.8× 219 1.3× 34 1.4k
L. Tybring Denmark 12 392 0.6× 238 0.5× 264 0.9× 167 0.8× 174 1.1× 24 917
P Labthavikul United States 22 653 1.0× 512 1.0× 353 1.3× 350 1.8× 280 1.7× 35 1.3k
Christopher Reading United States 13 875 1.3× 582 1.2× 640 2.3× 207 1.0× 154 0.9× 21 1.6k
Paul Actor United States 17 320 0.5× 177 0.4× 277 1.0× 167 0.8× 231 1.4× 72 988
Shōgo Kuwahara Japan 22 643 1.0× 346 0.7× 429 1.5× 447 2.2× 631 3.8× 82 1.7k
Barbara A. Pelak United States 14 302 0.5× 241 0.5× 329 1.2× 180 0.9× 205 1.3× 28 939
Peter Angehrn Switzerland 22 536 0.8× 603 1.2× 515 1.8× 246 1.2× 299 1.8× 53 1.5k

Countries citing papers authored by K. E. Price

Since Specialization
Citations

This map shows the geographic impact of K. E. Price's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. E. Price with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. E. Price more than expected).

Fields of papers citing papers by K. E. Price

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K. E. Price. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. E. Price. The network helps show where K. E. Price may publish in the future.

Co-authorship network of co-authors of K. E. Price

This figure shows the co-authorship network connecting the top 25 collaborators of K. E. Price. A scholar is included among the top collaborators of K. E. Price based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K. E. Price. K. E. Price is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wallace, Richard J., et al.. (2015). Mutational Resistance as the Mechanism of Acquired Drug Resistance to Aminoglycosides and Antibacterial Agents in Mycobacterium fortuitum and Mycobacterium chelonei. American Review of Respiratory Disease. 1 indexed citations
2.
Price, K. E.. (1986). Aminoglycoside research 1975-1985: prospects for development of improved agents. Antimicrobial Agents and Chemotherapy. 29(4). 543–548. 50 indexed citations
3.
Kessler, R E, R. E. Buck, T. A. Pursiano, et al.. (1985). Comparison of a new cephalosporin, BMY 28142, with other broad-spectrum beta-lactam antibiotics. Antimicrobial Agents and Chemotherapy. 27(2). 207–216. 141 indexed citations
4.
Leitner, F., et al.. (1980). Bactericidal activity of cefadroxil, cephalexin and cephradine in an in vitro pharmacokinetic model. Infection. 8(S5). S542–S548. 7 indexed citations
5.
Leitner, F., et al.. (1979). Bactericidal activity of cefadroxil, cephalexin, and cephradine in an in vitro pharmacokinetic model.. The Journal of Antibiotics. 32(7). 718–726. 14 indexed citations
6.
Leitner, F., et al.. (1976). Laboratory Evaluation of BL-S786, a Cephalosporin with Broad-Spectrum Antibacterial Activity. Antimicrobial Agents and Chemotherapy. 10(3). 426–435. 43 indexed citations
7.
Hirth, R. S., et al.. (1975). Pneumococcal Meningitis-Therapeutic Studies in Mice. Chemotherapy. 21(6). 342–357. 15 indexed citations
8.
Leitner, F., et al.. (1975). BL-S640, a Cephalosporin with a Broad Spectrum of Antibacterial Activity: Bioavailability and Therapeutic Properties in Rodents. Antimicrobial Agents and Chemotherapy. 7(3). 306–310. 19 indexed citations
9.
Pursiano, T. A., M Misiek, F. Leitner, & K. E. Price. (1973). Effect of Assay Medium on the Antibacterial Activity of Certain Penicillins and Cephalosporins. Antimicrobial Agents and Chemotherapy. 3(1). 33–39. 24 indexed citations
10.
Siminoff, Paul, et al.. (1973). BL-20803, a New, Low-Molecular-Weight Interferon Inducer. Antimicrobial Agents and Chemotherapy. 3(6). 742–743. 27 indexed citations
11.
Price, K. E., et al.. (1972). MICROBIOLOGICAL EVALUATION OF BB-K 8, A NEW SEMISYNTHETIC AMINOGLYCOSIDE. The Journal of Antibiotics. 25(12). 709–731. 66 indexed citations
12.
Godfrey, John C., et al.. (1971). Structure-activity relationships in chemically modified coumermycin. Pure and Applied Chemistry. 28(4). 571–602. 10 indexed citations
13.
Price, K. E., et al.. (1970). Semisynthetic Coumermycins: Structure-Activity Relationships. Applied Microbiology. 19(1). 14–26. 5 indexed citations
14.
Price, K. E., et al.. (1969). Antipseudomonal Activity of α-Sulfoaminopenicillins. Applied Microbiology. 17(6). 881–887. 4 indexed citations
15.
Price, K. E., et al.. (1969). Antipseudomonal Activity of α-Sulfoaminopenicillins. Applied Microbiology. 17(6). 881–887. 11 indexed citations
16.
Schmitz, H, William T. Bradner, A. Gourévitch, et al.. (1962). Actinogan: a new antitumor agent obtained from Streptomyces. I. Chemical and biological properties.. PubMed. 22. 163–6. 7 indexed citations
17.
Donovan, G.A., et al.. (1962). Antibiotic Potentiation. Poultry Science. 41(2). 546–555. 6 indexed citations
18.
Price, K. E., et al.. (1959). Influence of Oleandomycin and Penicillin on Intestinal Tract Microflora of Chickens. Poultry Science. 38(4). 873–877. 1 indexed citations
19.
Price, K. E., et al.. (1959). Antibiotic inhibitors. III. Reversal of calcium inhibition of intestinal absorption of oxytetracycline in chickens by certain acids and acid salts.. 5 indexed citations
20.
Hansen, P. Arne, et al.. (1952). SUITABLE THIOGLYCOLATE MEDIA FOR THE CULTIVATION OF VIBRIO FETUS. Journal of Bacteriology. 64(5). 772–772. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026